Consumer Portfolio Services’ Board of Directors Unanimously Rejects Unsolicited Indication of Interest from Auto Experience Inc.

LAS VEGAS, Nov. 11, 2020 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that its board of directors unanimously rejected Auto Experience Inc.’s (“AEI”) unsolicited indication of interest in acquiring the Company. 

After careful review and consideration, the CPS board concluded that AEI’s indicated price of $135 million grossly undervalues the Company. Taking into account the Company’s long-term prospects, the board determined that pursuing such a transaction would not be in the best interests of the Company’s shareholders. In addition, the CPS board does not believe that AEI’s indication of interest is credible.


About Consumer Portfolio Services, Inc.

Consumer Portfolio Services, Inc. is an independent specialty finance company that provides indirect automobile financing to individuals with past credit problems, low incomes or limited credit histories. CPS purchases retail installment sales contracts primarily from franchised automobile dealerships secured by late model used vehicles and, to a lesser extent, new vehicles. CPS funds these contract purchases on a long-term basis through the securitization markets and services the loans over their entire contract terms.


Investor Relations Contact

Jeffrey P. Fritz, Chief Financial Officer
844-878-CPSS (844-878-2777)

PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 11:20 a.m. EST.

The event will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com.

Investor Contact:

John Sharp

PhaseBio Pharmaceuticals, Inc.

Chief Financial Officer

(610) 981-6506

[email protected]

Media Contact:

Will Zasadny

Canale Communications, Inc.

[email protected]

619-961-8848

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Science Cardiology Other Science Biotechnology Research Pharmaceutical General Health Health

MEDIA:

Logo
Logo

Leagh Turner Appointed to Manulife’s Board of Directors

PR Newswire

C$ unless otherwise stated 
TSX/NYSE/PSE: MFC     SEHK: 945

TORONTO, Nov. 11, 2020 /PRNewswire/ – Manulife today announced that Leagh Turner has been appointed to its Board of Directors, effective November 10, 2020.

A seasoned global executive in the technology sector, Ms. Turner currently holds the position of President and Chief Operating Officer for Ceridian HCM Holding Inc., a global human capital management software company. She is also a strong advocate for the advancement of women in leadership and has been recognized twice on the WXN (Women’s Executive Network) Canada’s Top 100 Most Powerful Women list.

“Leagh brings extensive leadership expertise leveraging people, process and technology to drive organizational transformation. This expertise will be exceptionally valuable in supporting Manulife’s strategy and especially our focus on being a digital customer leader,” said John Cassaday, Chairman of the Board, Manulife. “We are delighted to welcome her to our Board.”

Ms. Turner joins the Manulife Board’s Management Resources and Compensation Committee and Risk Committee.

Visit Manulife.com for more information on the Company’s Board of Directors and Corporate Governance.

About Manulife

Manulife Financial Corporation is a leading international financial services group that helps people make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across our offices in Canada, Asia, and Europe, and primarily as John Hancock in the United States. We provide financial advice, insurance, and wealth and asset management solutions for individuals, groups and institutions. At the end of 2019, we had more than 35,000 employees, over 98,000 agents, and thousands of distribution partners, serving almost 30 million customers. As of September 30, 2020, we had $1.3 trillion (US$943 billion) in assets under management and administration, and in the previous 12 months we made $31.2 billion in payments to our customers. Our principal operations are in Asia, Canada and the United States where we have served customers for more than 155 years. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges and under ‘945’ in Hong Kong.

Cision View original content:http://www.prnewswire.com/news-releases/leagh-turner-appointed-to-manulifes-board-of-directors-301171387.html

SOURCE Manulife Financial Corporation

Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20





Event


will provide an overview


of how


A


s


cendis


is applying


its


TransCon
technology platform and itsunique algorithm for product innovation to the therapeutic area of oncology

COPENHAGEN, Denmark, Nov. 11, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will host a virtual Oncology R&D Day on Friday, November 20, 2020.

The event will provide an overview on the company’s strategy to apply the TransCon technology platform, which has been clinically validated in endocrinology rare disease, to our second therapeutic area of oncology to create product opportunities that have the potential to represent a paradigm shift in treating patients with cancer.

The event will include updates on Ascendis’ two leading oncology programs: TransCon TLR7/8 Agonist and TransCon IL-2 β/γ, for long-lasting activation of Toll-like receptor (TLR)7/8 or interleukin-2 ( IL-2) receptor β/γ, respectively.

Oncology
R&D
Day
Conference Call and Webcast information

Ascendis Pharma will host a conference call and webcast on Friday, November 20, 2020 at 12:00 p.m. Eastern Time (ET) to provide an overview and update the company’s oncology product pipeline. Details include:

Date November 20, 2020
Time 12:00 p.m. to 1:30 p.m. ET
Dial In (U.S.) 844-290-3904
Dial In (International) 574-990-1036
Access Code 8695366

A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

About Ascendis Pharma A/S 

Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs. Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.

For more information, please visit www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ strategy to create product opportunities that have the potential to represent a completely new paradigm shift in treating patients with cancer, (ii) Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharmaceutical company, (iii) Ascendis’ product pipeline and expansion into additional therapeutic areas and (iv) Ascendis’ expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis’ ability to obtain additional funding, if needed, to support its business activities and the effects on its business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on July 9, 2020 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on April 3, 2020. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © November 2020 Ascendis Pharma A/S.


Investor contacts:

Media contact:
Tim Lee Ron Rogers
Ascendis Pharma Ascendis Pharma
(650) 374-6343 (650) 507-5208
[email protected] [email protected]
   
Patti Bank  
Westwicke Partners  
(415) 513-1284  
[email protected]  
[email protected]  

ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action – BMRN

ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action – BMRN

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”), of the important November 24, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for BioMarin investors under the federal securities laws.

To join the BioMarin class action, go to http://www.rosenlegal.com/cases-register-1960.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (3) as a result, BioMarin’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1960.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

TerraForm Power Operating 2020 Third Quarter Results Webcast and Conference Call

Date:
Monday
,
November
1
6
,
20
20

Time:
9
:
0
0 a.m. (Eastern Time)

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — You are invited to participate in TerraForm Power Operating, LLC’s 2020 Third Quarter Results Webcast and Conference Call on Monday, November 16, 2020 at 9:00 a.m. (Eastern Time) to discuss results and current business initiatives with senior management.

These results will be made available on our website at www.terraformpower.com in the form of a quarterly report under “Financials & SEC Filings” in advance of the conference call.

The conference call can be accessed via webcast on November 16, 2020 at 9:00 a.m. (Eastern Time) at https://edge.media-server.com/mmc/p/2s4ygu8m. A replay of the webcast will be available for those unable to attend the live webcast. To participate via teleconference, please dial 1-844-464-3938 toll free in North America, or 1-765-507-2638 for overseas calls at approximately 8:50 a.m. Eastern Time; conference ID: 2059989.

About TerraForm Power
Operating, LLC

TerraForm Power Operating, LLC owns and operates a renewable power portfolio of solar and wind assets located primarily in North America and Western Europe. The company is a controlled affiliate of Brookfield Renewable Partners L.P. For more information, please visit: www.terraformpower.com.

Contact for Investors / Media:

Sherif El-Azzazi
TerraForm Power Operating, LLC
[email protected]

T-Mobile US, Inc. to Present at the BCG and New Street Research 5G Conference

T-Mobile US, Inc. to Present at the BCG and New Street Research 5G Conference

BELLEVUE, Wash.–(BUSINESS WIRE)–
Neville Ray, president of technology of T-Mobile US, Inc. (NASDAQ: TMUS), will present and provide a business update on Tuesday, November 17, 2020 at 11:20 a.m. Eastern Time (ET) at the BCG and New Street Research 5G Conference.

A live webcast of the virtual event will be available on the Company’s Investor Relations website at http://investor.t-mobile.com. An on-demand replay will be available shortly after the conclusion of the presentation.

To automatically receive T-Mobile financial news by e-mail, please visit the T-Mobile Investor Relations website, http://investor.t-mobile.com, and subscribe to E-mail Alerts.

About T-Mobile US, Inc.

T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: http://www.t-mobile.com.

Investor Contact:

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Mobile/Wireless Technology Telecommunications

MEDIA:

Logo
Logo

Company Profile for Smith Micro Software, Inc.

Company Profile for Smith Micro Software, Inc.

–(BUSINESS WIRE)–
Smith Micro develops software to simplify and enhance the mobile experience, providing solutions to some of the leading wireless service providers and cable MSOs around the world. From enabling the family digital lifestyle to providing powerful voice messaging capabilities, our solutions enrich today’s connected lifestyles while creating new opportunities to engage consumers via smartphones and consumer IoT devices. The Smith Micro portfolio also includes a wide range of products for creating, sharing and monetizing rich content, such as visual voice messaging, optimizing retail content displays and performing analytics on any product set.

Company:

Smith Micro Software, Inc.

 

Headquarters Address:

 

5800 Corporate Drive

Pittsburgh, PA 15237

 

Main Telephone:

+1 412-837-5300

 

Website:

https://www.smithmicro.com/

 

Ticker:

(NASDAQ: SMSI)

 

Type of Organization: 

Public

IRPR

 

Industry:

Software

 

Key Executives:

 

 

Chairman, President & CEO: William Smith Jr.

CFO: Timothy Huffmyer

VP, Investor Relations: Charles Messman

 

Investor Relations

 

Contact:

Phone:

Email:

Charles Messman

+1 949-362-2306

[email protected]

 

 

Financial Reporting

 

Contact:

Phone:

Email:

Jennifer Ganoe

+1 412-837-5331

[email protected]

 

 

Public Relations

 

Contact:

Phone:

Email:

Paula Yurkovich

+1 412-837-5393

[email protected]

 

 

Social Media

 

Twitter:

@smithmicro

Cashtag:

$SMSI

 

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Internet Consumer Electronics Mobile/Wireless Technology Software

MEDIA:

Logo
Logo

Tortoise Announces Proposed Merger of NDP and TTP with Strategy Change to Focus on the Global Energy Evolution

Tortoise Announces Proposed Merger of NDP and TTP with Strategy Change to Focus on the Global Energy Evolution

LEAWOOD, KS–(BUSINESS WIRE)–
Tortoise announced today that following a strategic review of the funds, the Board of Directors has approved a proposal to merge Tortoise Energy Independence Fund, Inc. (NDP) with and into Tortoise Pipeline & Energy Fund, Inc. (TTP). The newly combined fund will have an investment strategy to invest in those companies the team believes are in a position to benefit from the energy evolution taking place across the globe, and be renamed The Tortoise Energy Evolution Infrastructure Fund.

“We believe that merging these two funds is in the best interest of stockholders as it provides the opportunity to participate in the global energy evolution that is underway,” said Brad Adams, CEO of Tortoise’s closed-end funds. “The strategy will give the portfolio exposure to what the investment team believes are the best growth and value opportunities in renewables and midstream energy companies globally. We anticipate the fund will deliver a strong total return profile with an attractive yield and lower overall volatility, which we think is a great combination.”

The fund will invest in global stocks that operate essential renewable and power infrastructure such as solar and wind generation as well as energy infrastructure like liquefied natural gas (LNG) export facilities. These sectors are transitioning the energy sector toward solar, wind, and natural gas and away from coal, accelerating the reduction of global CO2 emissions.

“Tortoise’s long history of investing in energy infrastructure, including renewables and power as well as midstream energy infrastructure, positions us well to invest in the energy evolution,“ said Rob Thummel, Senior Portfolio Manager. The future of energy is driven by the need to meet growing global energy demand while simultaneously reducing CO2 emissions. We think the combination of renewable energy sources with power infrastructure, which includes low-carbon natural gas used domestically and exported across the globe and utilities in transition that are transforming their businesses to create a greener electric grid, is the most pragmatic way to accomplish this goal.”

On completion of the proposed merger, the adviser intends to recommend that the Board of Directors increase the quarterly distribution to $0.1925 per share, an increase of 20.3%, beginning the fiscal 2nd quarter of 2021. In addition, the adviser has agreed to lower its management fee 0.10% to 1.00% of average managed assets. The reduced management fee, and other expected cost savings, are estimated to be approximately $400,000 annually, or $0.10 per pro forma share. In addition to the estimated costs savings, the proposed merger may provide improved liquidity, long-term distribution growth potential, as well as a modest leverage profile.

“This strategic shift is aligned with our ongoing effort to narrow the discounts at which these closed-end funds are trading,” said Adams. “Our research suggests that funds with exposure to renewables and power infrastructure have been trading closer to net asset value.” In addition, the Board is committed to the repurchase programs approved for certain closed-end funds and has authorized the extension of TTP’s current repurchase program through the first quarter of 2021.

The Board of Directors and Tortoise believe that the proposed merger is in the best interests of stockholders of each fund. Details regarding the factors considered by the Board of Directors in connection with the merger proposal will be contained in proxy materials that will be sent to stockholders of each fund. For more information, an FAQ document and video are available here.

Tortoise Capital Advisors, L.L.C. is the adviser to the funds.

For additional information on these funds, please visit cef.tortoiseecofin.com.

About Tortoise

Tortoise focuses on energy and power infrastructure and the transition to cleaner energy. Tortoise’s solid track record of energy value chain investment experience and research dates back more than 20 years. As one of the earliest investors in midstream energy, Tortoise believes it is well-positioned to be at the forefront of the global energy evolution that is underway. With a steady wins approach and a long-term perspective, Tortoise strives to make a positive impact on clients and communities. For additional information, please visit www.TortoiseEcofin.com.

Important Information About the Proposed Merger and Where to Find It:

More information on the proposed merger will be contained in the proxy materials expected to be filed in the coming weeks. TTP plans to file in the near future with the Securities and Exchange Commission (SEC) a joint proxy statement/prospectus on Form N-14 8C with respect to the merger, and each fund expects to mail a definitive joint proxy statement/prospectus to each of its stockholders that will contain information about the proposed merger following a review period with the SEC. Stockholders are urged to read the definitive joint proxy statement/prospectus carefully and in its entirety when available as it will contain important information about the proposed merger. When filed with the SEC, the joint proxy statement/prospectus and other documents filed by the funds will be available for free at the SEC’s Web site, http://www.sec.gov and on the funds’ website at cef.tortoiseecofin.com. Stockholders can also obtain copies of the definitive joint proxy statement/prospectus, when available, for free by dialing (866) 362-9331.

The funds, Tortoise Capital Advisors and certain of their respective directors, officers and affiliates may be deemed under the rules of the SEC to be participants in the solicitation of proxies from stockholders in connection with the proposed merger discussed herein. Information about the directors and officers of the funds may be found in their respective annual reports and proxy statements previously filed with the SEC.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, included herein are “forward-looking statements.” Although the funds and Tortoise Capital Advisors believe that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the fund’s reports that are filed with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required by law, the funds and Tortoise Capital Advisors do not assume a duty to update this forward-looking statement.

Safe Harbor Statement

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

Maggie Zastrow

(913) 981-1020

[email protected].

KEYWORDS: United States North America Kansas

INDUSTRY KEYWORDS: Energy Professional Services Oil/Gas Finance

MEDIA:

Logo
Logo

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. – IPHA

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Innate and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On October 23, 2018, Innate and AstraZeneca plc (“AstraZeneca”) announced an expansion of a pre-existing collaboration agreement between the two companies, pursuant to which AstraZeneca purchased 9.8% of a newly-issued equity stake in Innate and obtained, among other things, full oncology rights to monalizumab, a first-in-class humanized anti-NKG2A antibody.  As part of this agreement, Innate was to receive $100 million in milestone payments at the start of the first Phase 3 clinical trial for monalizumab.  Then,  on September 8, 2020, Innate issued a press release announcing, in relevant part, that Innate and AstraZeneca had amended their collaboration agreement, such that Innate “will now receive a $50 million payment upon AstraZeneca’s dosing of the first patient in the Phase 3 trial, and a $50 million payment after the interim analysis demonstrates the combination meets a pre-defined threshold of clinical activity.” 

On this news, Innate’s American Depositary Share (“ADS”) price fell $1.62 per share, or 26.6%, to close at $4.45 per ADS on September 8, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980